13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • GSK Breast

    Acronym: 

    GSK Breast

    ACTRN/NCT /ethics: 

    Ethics: 141.17

    Scientific title: 

    A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer

    Summary of trial and patient characteristics

    Cancer Type Breast
    Trial Type Treatment
    Phase Phase I, Phase II Tumour Stream Breast
    Age Range 18 years and older Cancer Stage
    Sex Female Anticipated Start Date
    Molecular Target Anticipated End Date
    Cancer Type Breast
    Trial Type Treatment
    Phase Phase I, Phase II
    Age Range 18 years and older
    Sex Female
    Molecular Target
    Tumour Stream Breast
    Cancer Stage
    Anticipated Start Date
    Anticipated End Date

    Trial Summary

    A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer

    Lay Summary

    A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer

    Sponsor / Cooperative group

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Flinders Medical Centre Alex Scott-Hoy alex.scott-hoy@sa.gov.au 08 8204 4830 Bogda Koczwara Recruiting